CAR T company Autolus raises $80M series C

On Sept. 26, chimeric antigen receptor (CAR) T cell therapy company Autolus Ltd. (London, U.K.) raised $80 million in a series C round from new investors Cormorant Asset Management and Nextech Invest and existing investors Syncona Ltd., Woodford Investment Management and Arix Bioscience...